News

Partner companies' news

Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase 2A Trial for the Treatment of Gastroparesis

Acorn Management Partners, Administrator
April 2022 — 579 views PCSA

SAB Biotherapeutics Appoints Mark J. Ratain, MD, to the Company’s Board of Scientific Advisors

Acorn Management Partners, Administrator
April 2022 — 637 views SABS

Foresight Announces Fourth Quarter and Full Year 2021 Financial Results

Acorn Management Partners, Administrator
April 2022 — 620 views FRSX

KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates

Acorn Management Partners, Administrator
April 2022 — 638 views KMPH

Processa Pharmaceuticals Announces Year-End 2021 Results and Provides Corporate Update

Acorn Management Partners, Administrator
April 2022 — 598 views PCSA

SAB Biotherapeutics Provides Company Update and Reports Full Year 2021 Financial Results

Acorn Management Partners, Administrator
April 2022 — 575 views SABS

KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference

Acorn Management Partners, Administrator
March 2022 — 634 views KMPH

Processa Pharmaceuticals To Host Conference Call to Discuss Fourth Quarter 2021 Results and Provide Drug Development Update on March 30 at 4:30 p.m. EST

Acorn Management Partners, Administrator
March 2022 — 531 views PCSA

KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial

Acorn Management Partners, Administrator
March 2022 — 681 views KMPH

KemPharm Earns $1.975 Million Fee from Corium Following FDA Approval of the Corium Product ADLARITY® (donepezil transdermal system)

Acorn Management Partners, Administrator
March 2022 — 619 views KMPH

Foresight to Present and Participate in a Panel Discussion at the Maxim Group Virtual Growth Conference

Acorn Management Partners, Administrator
March 2022 — 638 views FRSX

Processa Pharmaceuticals CEO Dr. David Young To Present at the Oppenheimer 32nd Annual Healthcare Conference

Acorn Management Partners, Administrator
March 2022 — 601 views PCSA

KemPharm to Report Fourth Quarter and Full-Year 2021 Results

Acorn Management Partners, Administrator
March 2022 — 656 views KMPH

Foresight’s Technology to Replace Use of LiDAR by a Leading Israeli Defense Integrator for the Israeli Defense Forces

Acorn Management Partners, Administrator
February 2022 — 648 views FRSX

KemPharm Completes KP1077 Pre-IND Meeting Process with FDA

Acorn Management Partners, Administrator
February 2022 — 639 views KMPH

Foresight: Eye-Net Selected by Paris2Connect Consortium to Participate in an Urban Mobility Experiment, Consortium Members Include Nokia, ATC France, Aximum, RATP Group and Signify

Acorn Management Partners, Administrator
February 2022 — 578 views FRSX

Foresight Collaborates with a Leading Tier One Supplier on Enhancing ADAS Vision Systems

Acorn Management Partners, Administrator
February 2022 — 704 views FRSX

KemPharm Issues Letter to Shareholders Detailing Strategic Focus on CNS/Rare Disease Indications and Updated Clinical Development Strategy

Acorn Management Partners, Administrator
January 2022 — 634 views KMPH

Foresight and SUNWAY-AI Collaborate to Commercialize Autonomous Technologies to the Chinese Agriculture Market

Acorn Management Partners, Administrator
January 2022 — 617 views FRSX

KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion

Acorn Management Partners, Administrator
January 2022 — 653 views KMPH

About us

Helping America invest in you:

Connecting your company stock with professional market participants.

One call at a time

Stay updated :

Participate on our social stream.

Our Blogs

Tags

Archives